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Background: DNA methylation is a heritable and stable epigenetic mark implicated in complex human traits.
Epigenome-wide association studies (EWAS) using array-based technology are becoming widely used to identify
differentially methylated sites associated with complex diseases. EWAS studies require large sample sizes to detect
small effects, which increases project costs. In the present study we propose to pool DNA samples in methylation
array studies as an affordable and accurate alternative to individual samples studies, in order to reduce economic
costs or when low amounts of DNA are available. For this study, 20 individual DNA samples and 4 pooled DNA
samples were analysed using the Illumina Infinium HumanMethylation450 BeadChip array to evaluate the efficiency
of the pooling approach in EWAS studies. Statistical power calculations were also performed to discover the
minimum sample size needed for the pooling strategy in EWAS.
Results: A total of 485,577 CpG sites across the whole genome were assessed. Comparison of methylation levels of
all CpG sites between individual samples and their related pooled samples revealed highly significant correlations
(rho > 0.99, p-val < 10−16). These results remained similar when assessing the 101 most differentially methylated CpG
sites (rho > 0.98, p-val < 10−16). Also, it was calculated that n = 43 is the minimum sample size required to achieve a
95 % statistical power and a 10−06 significance level in EWAS, when using a DNA pool strategy.
Conclusions: DNA pooling strategies seems to accurately provide estimations of averaged DNA methylation state
using array based EWAS studies. This type of approach can be applied to the assessment of disease phenotypes,
reducing the amount of DNA required and the cost of large-scale epigenetic analyses.Background
Epigenetics refers to the stable, heritable and reversible
modifications in DNA expression associated with
transcriptional regulation without alterations in the nu-
cleotide sequence [1]. Epigenetic processes such as DNA
methylation (DNAm), histone acetylation/deacetylation,
non-coding mRNA expression and chromatin conform-
ational changes [2] are essential for normal cellular de-
velopment and differentiation. They have also been* Correspondence: israelcadenas@yahoo.es
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[3, 4]. Nowadays DNA methylation is one of the most
studied epigenetic modifications [5, 6] and alterations in
methylation have been linked with some disease pro-
cesses such as different types of cancer [4, 7, 8], as well
as with aging and exposure to tobacco smoke [9–12].
Some of the most important technologies used to de-
tect DNA methylation are: deep sequencing, high-
throughput deep sequencing and array-based genome-
wide studies such as Epigenome Wide Association
(EWAS) [13].
In the “omics” era, Genome-wide Association Studies
(GWAS) have been widely used to discover the genetic
polymorphisms associated with human diseases. TheseAccess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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ated with complex diseases, compared to classical candidate
genes studies. However, GWAS needs higher sample sizes
and specific arrays that increase project costs. Several pa-
pers have observed that the use of pooling strategies de-
creases the cost of GWAS, while providing similar results
to individual sample analysis [14].
Pearson and colleagues reported that pooling-based
GWAS was theoretically effective in identifying genetic
associations in different types of disease [15]. Applying
these methods to experimental case–control data, they
also demonstrated the successful identification of previ-
ously published susceptible loci for a rare monogenic
disease, a rare complex disease and a common complex
disease. In addition, Gaj et al. confirmed previously re-
ported loci for colorectal cancer and prostate cancer in a
Polish population, with a pooled-based strategy using
GWAS [16].
Epigenome-wide association studies (EWAS) use the
same strategy as GWAS, but for epigenetics. EWAS use
array-based genotyping technology to detect the methy-
lation levels at CpG sites across the genome. EWAS
of human diseases are becoming increasingly common
[4, 7, 17, 18]. Like GWAS, the EWAS are hypothesis-
free approaches to finding differentially methylated sites
instead of different allele frequencies. Nevertheless,
pooled DNA strategies might be an affordable alternative
that reduces study costs in array-based EWAS.
No current studies have analysed the accuracy of DNA
pooling strategies in array-based EWAS. Our aim is thus
to analyse the pooling strategies in EWAS studies in order
to determine the effectiveness of these approaches in
studying DNA methylation patterns in human samples.
In the present study, data from 20 individual DNA
samples and 4 pooled DNA samples, analysed with the
Illumina Infinium HumanMethylation450 BeadChip,
were used to estimate the feasibility of the pooling ap-
proach, comparing the results of the individual samples
to the results of the DNA pools of the same samples.
Results and discussion
Quality control
A total of 485,577 CpG sites across the whole genome
were assessed using the Illumnia HumanMethylation450
BeadChip, in 20 individual samples and 4 DNA pools.
First, the distribution of methylation level was evaluated
for all samples, with DNA pools showing the same be-
haviour as individual samples (Fig. 1). Before the quan-
tile normalization, 33,301 CpG sites and no samples
were removed due to QC issues.
Correlations
Data revealed highly significant correlations (p-value < 10−16,
Spearman’s test) after comparing the data generated fromthe pooled DNA samples with the averaged results of the
individual samples. Group A and group B samples were
studied separately with their respective pools, the obtained
correlations were rho = 0.9922 (p-values < 10−16) for group
B and rho = 0.9914 (p-value < 10−16) for group A. (Fig. 2).
In addition, a second confirmation test was performed
to assess the potential to estimate accurate β-values in
the most significant differentially methylated CpGs when
using a DNA pool strategy in EWAS. A comparison
between all CpGs between group A and group B was
performed and the most significant CpG sites (n = 101),
p-val < 10−05, were selected. Highly significant correla-
tions (p-val < 10−16) were also observed when analysing
the 101 selected CpGs between group A and their
pooled samples and between group B and their pooled
samples (Group A: rho = 0.9808, p-value < 10−16; Group
B: rho = 0.9872, p-value < 10−16) (Fig. 3).
Sample size
Using values from the most significant DMC of pooled
samples in the EWAS study, the optimum sample size to
reach a 95 % statistical power and a 10−6 significance
level, should be from 43 to 100 pooled samples per con-
dition, considering Cohen’s d effect sizes of 1.5 to 0.95
respectively.
The accuracy and reproducibility of DNA pools for
methylation array, using the Illumina Infinium Human-
Methylation450 BeadChip array, was investigated by
comparing data obtained from individual samples and
the same samples after they had been pooled.
Our data indicate that the DNA methylation profile
(β-values of CpG sites) from the pooled DNA samples
using array technology are highly consistent with
those obtained from the individual samples, even when
evaluating the most significant DMCs separately (Group
A: rho = 0.9808, p-value < 10−16; Group B: rho = 0.9872,
p-value < 10−16).
A previous study analysing pooling strategies in methy-
lation studies demonstrated that pools could be an alter-
native technique when small amounts of DNA are
available or when a reduction in cost is necessary to
undertake the experiments. In the study, Docherty et al.
showed a correlation between 89 individual samples and 4
pool samples in 205 CpG sites spanning 9 genomic re-
gions using Sequenom EpiTYPER [19]. The overall correla-
tion value in the study was 0.95 with a p-value < 2.210−16,
similar to the results that we observed. However, in our
study we found that pooling strategies can be also per-
formed assessing whole genomes in array-based EWAS ex-
periments, analysing more than 450,000 CpG sites. This
finding expands the possibilities of Genome Wide
studies in epigenetics. In a pooling-based GWAS study,
Pearson et al. demonstrated successful identification of
published genetic susceptibility loci for some human
Fig. 1 Density distribution of β-values. a Density distribution of β-values across all the 485,577 CpG sites of the 20 samples and the four pools.
b Distribution of five samples of group A and their respective pool. c Distribution of five samples of group B and their respective pool. The black
lines represent the distribution of pools and the grey lines represent the distribution of samples. The X-axis represents the average methylation
β-value and the Y-axis the density
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sive supranuclear palsy and TSPYL in sudden infant death
with dysgenesis of the testes syndrome (SIDDT) [15]. In
EWAS we have yet to confirm whether previously reported
genes can be found using pooling strategies. However, the
higher correlation of the methylation levels between pools
and individual samples indicates that the pooling strategiesin EWAS are an accurate and interesting strategy to reduce
time costs and DNA amount in such experiments.
Even though a DNA pooling strategy has important
advantages, there are several drawbacks that have to be
considered in the study design. Pool construction has to
be really precise. DNA quantities have to be really accur-
ate to assure that each sample in the pool provides equal
Fig. 2 Correlations for 450 k CpG sites. Correlations between averaged β-values of individual samples and averaged β-values of pools. a Correlations
for group A samples and their pools. b Correlation for group B samples and their pools. The X-axis represents the average methylation β-value for
individual samples; the Y-axis represents the average methylation β-value for pools
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that may alter the estimated methylation levels [14, 20].
Only mean methylation levels, and not individual methy-
lation data, can be obtained from pooled samples. In
addition, adjusting for covariates is almost impossible,
unless pooled samples are very homogeneous. Popula-
tion stratification needs to be excluded. Furthermore,Fig. 3 Correlations for 101 DMCs. Correlations between averaged β-values
significant DMCs. a Correlations of 101 CpGs for group A samples and thei
pools. The X-axis represents the average methylation β-value for individual
for poolsthe error rate tends to be higher in pooled samples com-
pared to individual ones [21]. It is also important in the
study design for EWAS with pooled samples to take into
account the sample size needed to compute DMCs
with confidence. According to the results obtained
in our study, we suggest analysis of at least n = 43 pooled
samples per condition in order to achieve a 10−06of individual samples and averaged β-values of Pools, for the 101 most
r pools. b Correlations of 101 CpGs for group B samples and their
samples; the Y-axis represents the average methylation β-value
Table 1 Population characteristics
Total Group A Group B
Gender N 20 10(50 %) 10 (50 %)
Age 72,25 ± 8.4 72,5 ± 8.4 72 ± 8.7
Male 16 (80 %) 8 (40 %) 8 (40 %)
Female 4 (20 %) 2 (10 %) 2 (10 %)
TOASTa Atherothrombotic 8 (40 %) 4 (20 %) 4 (20 %)
Undetermined 4 (20 %) 2 (10 %) 2 (10 %)
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a Cohen’s d effect size =1.5. However, this number may
vary depending on a study’s characteristics.
In summary, this is the first study that analyses a pool-
ing strategy in EWAS approaches, it found that this strat-
egy is an acceptable alternative to regular individual
EWAS analysis, mainly in specific situations such as when
lower quantities of DNA are available, or in studies with a
limited budget.Unknown 2 (10 %) 1 (5 %) 1 (5 %)
Lacunar 6 (30 %) 3 (15 %) 3 (15 %)
Demographic and clinical variables of the studied population
aTOAST classification of ischemic strokeConclusions
The analysis of the data generated by 450,000 CpG sites
across the whole genome in 20 individual samples dem-
onstrates that DNA pooling strategies can be used to
provide estimations of averaged DNA methylation state
using the Illumina Infinium HumanMethylation450
BeadChip array. This approach may be useful to high-
light genome regions to be studied in further epigenetic
analysis, reducing the costs and the amount of DNA
required.Methods
Sample selection and pool construction
A total of 20 subjects from our biobank were selected.
Of these 20 subjects, 10 were ischemic stroke patients
with vascular recurrence (this selection was performed
randomly from the patients with vascular recurrence)
(group A). These patients were then matched one-to-
one with 10 ischemic stroke patients without vascular
recurrence (group B). The matching categories were age
(±7 years), sex, TOAST classification [19] and recruit-
ment hospital. Next, two pooled samples were con-
structed with samples from group A (PoolA1 and
PoolA2), and two pooled samples were constructed with
samples from group B (PoolB1 and PoolB2), as described
in Fig. 4. PoolB1 included the matched samples of
PoolA1 and correspondingly PoolB2 included the
matched samples of PoolA2. All individuals wereFig. 4 Study design. A total of 20 subjects from the biobank study were se
Two pools were created from group A, with 5 samples in each one (PoolA
group B (PoolB1 and PoolB2)Caucasian, while 16 were males and 4 were females,
mean age was 71 ± 8 years (Table 1).
DNA purification and sample pooling
Total genomic DNA was extracted from whole blood
samples using the Gentra Puregene Blood Kit (Quiagen,
Hilden, Germany) following the manufacturer’s instruc-
tions. The samples were maintained at −20 °C until the
EWAS analysis.
DNA concentrations for each subject were determined
individually, by measuring ultraviolet (UV) light absorp-
tion at 260 nm, with NanoDrop 2000 UV–vis Spectro-
photometer (Thermo Scientific, Redwood City, CA,
USA). Adapting the instructions of previous DNA pooling
protocols [14, 15], each sample was diluted to 40 ng/ul,
and their DNA concentration was measured again to ver-
ify that all samples provide the same amount of DNA to
the pools. Samples with DNA concentration variations
higher than 40 ng/μl ±4 were discarded and diluted again.
Individual DNA samples were then added to their respect-
ive pool (4 μl at 40 ng/μl of each sample). Once each pool
was generated, the DNA concentrations were re-
quantified twice with NanoDrop to assure that the final
concentration of the pool was as expected (40 ng/μl). If
any discrepancy was found (> ± 4 ng/μl), the pool waslected for this study, 10 of them form group A and 10 form group B.
1 and PoolA2), and two more pools of 5 samples were created from
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measures. Only when the final pool concentration was
40 ng/μl ±4 ng/μl and the total volume was 20 μl as
expected was the EWAS analysis started. A graphical
description of the procedure can be found in Fig. 5.
Epigenome wide association analysis
Genome-wide DNA methylation was assessed using the
Infinium HumanMethylation450 BeadChip (Illumina
Inc., San Diego, Ca). This chip-based study quantitatively
measures more than 450,000 CpG sites at single nucleo-
tide resolution with a 99 % coverage of RefSeq Genes.
A Quality Control (QC) of all samples was performed
as a first step to check DNA integrity using Invitrogen
E-Gel 1 % Agarose Gels. The DNA samples showed no
fragmentation or poor quality.
Genomic DNA from the 20 samples and the 4 pools
was bisulphite converted using the Zymo EZ DNA
MethylationTM Kit (Zymo Research, Orange, Ca) followingFig. 5 Protocol for performing DNA Pools. First, DNA concentrations of ind
absorption (Nanodrop spectrophotometer). When readings differ less than
prepared using 5ul of DNA from each of the 5 samples that would form pa
at 40 ng/μl, with DNA concentration checked by UV light absorption (Nano
±4 ng/μl, pools were analysed with the EWAS arrays. If readings differed, ththe manufacturer’s instructions, but with alternative incu-
bation conditions suggested for the Illumina Infinium
Methylation Assay. All samples were processed in a single
working batch using the Illumina Infinium MSA4 protocol,
which includes amplification, fragmentation, hybridization
and BeadChip scanning.
For QC, the fluorescence data generated for each CpG
locus was analysed with the Illumina GenomeStudio
software package. Samples and CpG sites with fluores-
cence detection p-values > 0.05 were removed [22]. This
p-vaule is the detection p-value that represents the con-
fidence that a given methylation level on a CpG site can
be considered to have been detected.
Quality control and normalization
All pre-processing, correction and normalization steps
were implemented using the R computing environment
(versions 2.15.1 and 3.0.1) with Bioconductor packages.
Plots were produced using R functions. The pipeline wasividual samples were measured three times by ultraviolet (UV) light
4 ng/μl, samples were diluted to 40 ng/μl. Next, the pools were
rt of the pool. The final concentration of every pool should be 25 μl
drop spectrophotometer) again. Finally, if readings were 40 ng/μl
e pools were created again from the first step
Table 2 R packages and instructions. Specific instructions used
from each R package
R package Instruction Description
methylumi methylumiR Load Illumina methylation data into a
MethyLumiSet object.
minfi densityPlot Density plots of methylation Beta values.
watRmelon pfilter Filter data sets based on bead count and
detection p-values
minfi mdsPlot Multi-dimensional scaling (MDS) plots
showing a 2-d projection of distances
between samples.
watRmelon dasen Calculate normalized betas from Illumina
450 K methylation arrays.
lumi estimateBetas Estimate methylation Beta-value matrix
from eSet-class object (include methylated
and unmethylated probe intensities)
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[23] (version 2.6.1), lumi [24] (version 2.12.0), water-
melon [25] (version 1.0.3) and minfi [22] (version 1.6.0)
packages. The instructions that were used are shown in
Table 2.
Prior to the identification of differentially methylated
CpG sites, data was pre-processed using a non-specific
filter step. This step consists of removing CpG sites with
detection p-value ≥ 0.05 in more than 1 % of the sam-
ples. Samples with detection p-value ≥ 0.05 in more than
1 % of the CpG sites, and CpG sites with beadCount < 3
in 5 % of samples [16]. CpG sites containing docu-
mented single nucleotide polymorphisms (SNPs) were
also removed [26]. Multidimensional scaling (MDS)
plots were used to evaluate gender outliers based on
chromosome X data, where males and females were sep-
arated into two distinct clusters. An MDS plot was also
used to check for unknown population structures, inside
the sample. Then, CpG sites on the X and Y chromo-
somes were removed [8]. Finally, a subset quantile
normalization was performed using a background ad-
justment between-array normalization and a dye bias
correction, following previous recommendations [27, 28].
Statistical analysis
All statistical analysis was also performed using R (version
3.0.1). The accuracy of DNA methylation level estimations
from pooled DNA was assessed with a Spearman’s correl-
ation, for non-parametric samples, between the β-values
of each pool and the averaged β-values of the individual
samples included in each pool [19].
We also performed a Spearman’s correlation between
the β-values of the 101 most differentially methylated
CpGs (DMCs) found in individual samples (Group A vs.
Group B) and the β-values of the same CpG sites in
pools. Differentially methylated CpG sites were deter-
mined by the Mann–Whitney U-test for non-parametricsamples using the β-values, p-val < 10−06 adapted from
Rakyan VK el al. [4]. The DMCs analysis was performed
comparing group A samples (n = 10) against group B
samples (n = 10).
Minimum sample size needed for pool analysis in
EWAS was calculated using the pwr package [29] with im-
plemented power analysis as outlined by J. Cohen, 1988.
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